A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.

@article{Wong2003API,
  title={A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.},
  author={Jeffrey Y. C. Wong and Stephen I. Shibata and Lawrence E. Williams and C. S. Kwok and An Liu and David Z. J. Chu and Dave M. Yamauchi and Sharon P. Wilczynski and David N. Ikle and Anna M Wu and Paul J. Yazaki and John E Shively and James H. Doroshow and Andrew A. Raubitschek},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 16 Pt 1},
  pages={5842-52}
}
PURPOSE Targeted systemic radiation therapy using radiolabeled antibodies results in tumor doses sufficient to produce significant objective responses in the radiosensitive hematological malignancies. Although comparable doses to tumor are achieved with radioimmunotherapy (RIT) in solid tumors, results have been modest primarily because of their relative lack of radiosensitivity. For solid tumors, as with external beam radiotherapy, RIT should have a more important clinical role if combined… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…